|
|
60 Hampshire Street
Cambridge, MA 02139 USA
phone:617-995-9800
fax:617-995-9801
|
|
| Symbol |
IDIX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.idenix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Developing treatments for human viral and infectious diseases. |
|
| Management |
| Jean-Pierre Sommadossi, Ph.D., Founder, CEO and Chairman; Ronald C.Renaud,Jr., Chief Financial Officer and Treasurer; Douglas L. Mayers, M.D., Executive Vice President and Chief Medical Officer; John F. Weidenbruch, Executive Vice President and General Counsel; Paul J. Fanning, Senior Vice President, Human Resources; David N. Standring, Ph.D., Executive Vice President, Biology |
| |
|
|
|
|
|
|
|
| Keywords |
| nucleoside, hepatitis B virus, HBV, hepatitis C virus, HCV, HIV, small molecule, oral, HIVAIDS |
|
|
|
| Description |
|
Idenix Pharmaceuticals is an independent biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. |
|
| Technology / Differentiation |
| Building on their expertise in nucleoside chemistry and biology and other small molecule therapeutic compounds their efforts focus on significantly advancing the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV infection through the development and commercialization of drugs that may be orally administered once a day. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
